Acesso livre
Acesso livre

Destaques

Cuidado intensivo das infecções respiratórias agudas graves (adaptação para COVID-19, atualização 2022).

12 Abr, 2022 | 12:40h

Clinical care of severe acute respiratory infections – Tool kit – World Health Organization

 

Comentário no Twitter (fio – clique para saber mais)

 

Estudo de caso-controle e teste negativo | Vacina CoronaVac mostrou-se efetiva em evitar COVID-19 grave e sintomática em gestantes no Brasil.

12 Abr, 2022 | 12:37h

CoronaVac vaccine is effective in preventing symptomatic and severe COVID-19 in pregnant women in Brazil: a test-negative case-control study – BMC Medicine

Estudo randomizado | Efeito da antibioticoterapia inicial guiada por coloração de Gram sobre a resposta clínica de pacientes com pneumonia associada a ventilador.

12 Abr, 2022 | 12:35h

Effect of Gram Stain–Guided Initial Antibiotic Therapy on Clinical Response in Patients With Ventilator-Associated Pneumonia: The GRACE-VAP Randomized Clinical Trial – JAMA Network Open

Comentário: Can Gram Stains Guide Antibiotics for Pneumonia in Critical Care? – Medscape (necessário cadastro gratuito)

 

Comentário no Twitter

 

Estudo randomizado | Em crianças criticamente doentes que necessitam de suporte respiratório não invasivo após extubação, a cânula nasal de alto fluxo NÃO foi não inferior ao CPAP, resultando em maior tempo de liberação do suporte respiratório.

11 Abr, 2022 | 13:07h

Effect of High-Flow Nasal Cannula Therapy vs Continuous Positive Airway Pressure Following Extubation on Liberation From Respiratory Support in Critically Ill Children: A Randomized Clinical Trial – JAMA (gratuito por tempo limitado)

Editorial: Selecting Intermediate Respiratory Support Following Extubation in the Pediatric Intensive Care Unit – JAMA (gratuito por tempo limitado)

Comunicado de imprensa: Trial identifies most effective breathing support for children in intensive care – Imperial College London

 

Comentário no Twitter

 

Estudo de coorte | Uso de inibidores da fosfodiesterase 2 está associado a risco aumentado de eventos adversos oculares.

11 Abr, 2022 | 13:05h

Risk of Ocular Adverse Events Associated With Use of Phosphodiesterase 5 Inhibitors in Men in the US – JAMA Ophthalmology (gratuito por tempo limitado)

Comunicado de imprensa: U.S. insurance claims show strong link between ED medications and vision problems – University of British Columbia

Comentários:

Phase 4 Studies on Phosphodiesterase 5 Inhibitors – JAMA Ophthalmology (gratuito por tempo limitado)

Expert reaction to study looking at risk of vision impairment and loss, and use of phosphodiesterase type 5 inhibitors – Science Media Centre

Análise sistemática para o Global Burden of Disease Study 2019 | Impacto global, regional e nacional do câncer colorretal e seus fatores de risco, 1990-2019.

11 Abr, 2022 | 13:03h

Global, regional, and national burden of colorectal cancer and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 – The Lancet Gastroenterology & Hepatology

Comentário convidado: Global epidemiology and prevention of colorectal cancer – The Lancet Gastroenterology & Hepatology (necessário cadastro gratuito)

Revisão do estado de arte | Prognóstico e tomada de decisão compartilhada no cuidado neurocrítico.

11 Abr, 2022 | 13:02h

Prognostication and shared decision making in neurocritical care – The BMJ

 

Comentário no Twitter

 

Fatores de risco e implicações prognósticas do câncer em 30 dias após uma internação hospitalar de emergência (apresentação emergencial).

11 Abr, 2022 | 13:00h

Risk factors and prognostic implications of diagnosis of cancer within 30 days after an emergency hospital admission (emergency presentation): an International Cancer Benchmarking Partnership (ICBP) population-based study – The Lancet Oncology

Comentário: Emergency presentations: what are they, and what do they mean for cancer survival? – Cancer Research UK

 

Comentário no Twitter (fio – clique para saber mais) – texto e imagens sob a licença de Creative Commons Attribution (CC BY 4.0)

 

M-A | Padrões de trombose e desfecho clínico da trombocitopenia trombótica imune induzida por vacina contra COVID-19.

11 Abr, 2022 | 12:58h

Thrombosis patterns and clinical outcome of COVID-19 vaccine-induced immune thrombotic thrombocytopenia: A Systematic Review and Meta-Analysis – International Journal of Infectious Diseases

Conteúdos relacionados:

Case series of Thrombosis with Thrombocytopenia Syndrome after Covid-19 vaccination in the US.

Review: Vaccine-induced immune thrombotic thrombocytopenia.

Vaccine induced immune thrombocytopenia and thrombosis: summary of NICE guidance.

Clinical features of vaccine-induced immune thrombocytopenia and thrombosis.

Review: Clinical characteristics and pharmacological management of COVID-19 vaccine–induced immune thrombotic thrombocytopenia with cerebral venous sinus thrombosis.

Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know.

Very rare cases of thrombosis with thrombocytopenia syndrome (TTS) after AstraZeneca vaccine: a global safety database analysis – the estimated rate of TTS after the first dose was 8.1 per million vaccinees; after the second dose, the estimated rate was 2.3 per million vaccinees. (vários artigos e fontes sobre o tema)

Consenso: COVID longa em crianças.

11 Abr, 2022 | 12:57h

Long COVID (post-COVID-19 condition) in children: a modified Delphi process – Archives of Disease in Childhood

Conteúdos relacionados:

First research definition for ‘Long COVID’ in kids and young people formally agreed.

Cohort Study: Physical and mental health 3 months after SARS-CoV-2 infection (long COVID) among adolescents in England.

A nationwide cohort study in Denmark showed Long Covid in children is rare and mainly of short duration.

Editorial | Long covid in children and adolescents – “Risk appears low, but many questions remain”.

M-A: Persistent symptoms following SARS-CoV-2 infection among children and young people – “Higher study quality was associated with lower prevalence of all symptoms, except loss of smell and cognitive symptoms”.

Review: Long COVID symptoms in children rarely persist beyond three months.

Cohort study: long term follow-up showed most patients with post–COVID-19 Multisystem Inflammatory Syndrome in Children had good outcomes with no significant medium- or long-term sequelae.

Do kids get long COVID? And how often? A pediatrician looks at the data – Children also get Long Covid, but much less often than adults.

Illness duration and symptom profile in symptomatic school-aged children tested for SARS-CoV-2 – “Only 25 (1.8%) of 1379 children experienced symptoms for at least 56 days.”

Long-term Symptoms After SARS-CoV-2 Infection in Children and Adolescents – “This study found a low prevalence of symptoms compatible with long COVID in a randomly selected cohort of children assessed 6 months after serologic testing”.

Study shows low incidence of post-acute COVID-19 symptoms (“Long Covid”) in children after mild disease

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.